{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:29:42Z","timestamp":1785896982945,"version":"3.56.0"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Globe-sparing radiotherapy is widely utilised in the treatment of uveal melanoma, but often results in complications requiring vitreoretinal intervention. The outcomes of secondary vitrectomy remain unclear. A multidisciplinary approach involving vitreoretinal and ocular oncology specialists is essential to managing complications. (2) Methods: We reviewed 1794 patients treated with radiotherapy for uveal melanoma between 2012 and 2022. In total, 70 patients underwent secondary vitrectomy after primary radiotherapy treatment. The outcomes included overall tumour control and visual outcome. (3) Results: Complications requiring vitrectomy were more common after proton-beam radiotherapy than plaque brachytherapy (5.4% versus 3.0%). Common indications included vitreous haemorrhage (39%) and retinal detachment\/toxic tumour syndrome (31%). The affected tumours were larger, more often ciliary body in origin, and associated with a worse prognosis. Vitrectomy patients had higher rates of enucleation (9% versus 3%), metastasis (16% versus 6%), and visual decline (average 0.60 LogMAR), with limited visual improvement (\u22653-line gain in 13%). Proton-beam patients had worse outcomes than plaque brachytherapy patients. (4) Conclusions: Vitreoretinal complications after uveal melanoma radiotherapy are rare, but timely treatment by those with experience may enable patients to keep their eye in situations where enucleation would be the only alternative. Patients and clinicians must understand the risks of complications to make informed decisions about treatment plans, with vitreoretinal surgeons and ocular oncologists key to outcomes.<\/jats:p>","DOI":"10.3390\/cancers18010095","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:47:27Z","timestamp":1766998047000},"page":"95","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vitreoretinal Surgery for Intraocular Complications Following Radiotherapy Treatment of Uveal Melanoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-6542","authenticated-orcid":false,"given":"Thomas Joseph","family":"Padley","sequence":"first","affiliation":[{"name":"Liverpool Ocular Oncology Centre, Prescott Street, Liverpool L7 8XP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana","family":"Hussain","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Centre, Prescott Street, Liverpool L7 8XP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Eleuteri","sequence":"additional","affiliation":[{"name":"Research & Innovation Department, NHS University Hospitals of Liverpool Group, Edwards Building, Liverpool L7 8YE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Da","family":"Chou","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Research Group, Department of Eye and Vision Science, Institute of Life Course and Medical Sciences (ILCaMS), University of Liverpool, Liverpool L7 8TX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Groenewald","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Centre, Prescott Street, Liverpool L7 8XP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Heimann","sequence":"additional","affiliation":[{"name":"Liverpool Ocular Oncology Centre, Prescott Street, Liverpool L7 8XP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ohc.2004.07.002","article-title":"Uveal melanoma: Epidemiologic aspects","volume":"18","author":"Singh","year":"2005","journal-title":"Ophthalmol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.64.13.45","article-title":"Rotterdam Ocular Melanoma Study Group. Worldwide Incidence of Ocular Melanoma and Correlation with Pigmentation-Related Risk Factors","volume":"64","author":"Wu","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/eye.2015.20","article-title":"Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland","volume":"29","author":"Chia","year":"2015","journal-title":"Eye"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ceo.14214","article-title":"Current management of uveal melanoma: A review","volume":"51","author":"Bai","year":"2023","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hanratty, K., Finegan, G., Rochfort, K.D., and Kennedy, S. (2025). Current Treatment of Uveal Melanoma. Cancers, 17.","DOI":"10.3390\/cancers17091403"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Group COMS (2006). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch. Ophthalmol., 124, 1684\u20131693.","DOI":"10.1001\/archopht.124.12.1684"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0161-6420(90)32512-5","article-title":"Relative survival rates after alternative therapies for uveal melanoma","volume":"97","author":"Seddon","year":"1990","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/IAE.0b013e318295f758","article-title":"Role of vitreoretinal surgery in maximizing treatment outcome following complications after proton therapy for uveal melanoma","volume":"33","author":"Tran","year":"2013","journal-title":"Retina"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zemba, M., Dumitrescu, O.-M., Gheorghe, A.G., Radu, M., Ionescu, M.A., Vatafu, A., and Dinu, V. (2023). Ocular Complications of Radiotherapy in Uveal Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15020333"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.3390\/curroncol30070470","article-title":"Radiotherapy in Uveal Melanoma: A Review of Ocular Complications","volume":"30","author":"Banou","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/eye.2009.43","article-title":"Ocular complications following I-125 brachytherapy for choroidal melanoma","volume":"23","author":"Wen","year":"2009","journal-title":"Eye"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/eye.2012.249","article-title":"Effects of radiotherapy on uveal melanomas and adjacent tissues","volume":"27","author":"Groenewald","year":"2013","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5114\/jcb.2022.115210","article-title":"Contemporary trends in management of uveal melanoma","volume":"14","author":"Chevli","year":"2022","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chan, A.W., Lin, H., Yacoub, I., Chhabra, A.M., Choi, J.I., and Simone, C.B. (2024). Proton Therapy in Uveal Melanoma. Cancers, 16.","DOI":"10.3390\/cancers16203497"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/cco.2016.07.06","article-title":"Proton therapy for the management of uveal melanoma and other ocular tumors","volume":"5","author":"Mishra","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40942-017-0096-5","article-title":"Outcomes of primary endoresection for choroidal melanoma","volume":"3","author":"Vidoris","year":"2017","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/0974-9233.65494","article-title":"Exoresection and endoresection for uveal melanoma","volume":"17","author":"Gunduz","year":"2010","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_19","first-page":"471","article-title":"Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma","volume":"136","author":"Foster","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archophthalmol.2012.2391","article-title":"Safety of pars plana vitrectomy in eyes with plaque-irradiated posterior uveal melanoma","volume":"130","author":"Bansal","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_21","first-page":"3274","article-title":"Safety of Pars Plana Vitrectomy in Eyes Containing a Treated Uveal Melanoma","volume":"52","author":"Rajagopal","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4274\/tjo.galenos.2021.24376","article-title":"Surgical Approach in Intraocular Tumors","volume":"52","author":"Mirzayev","year":"2022","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ophtha.2007.06.012","article-title":"Cytogenetics of uveal melanoma: A 7-year clinical experience","volume":"114","author":"Damato","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","article-title":"Prognostic implications of monosomy 3 in uveal melanoma","volume":"347","author":"Prescher","year":"1996","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.ophtha.2018.03.047","article-title":"Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma","volume":"125","author":"Bagger","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/eye.2015.3","article-title":"The Royal College of Ophthalmologists\u2019 National Ophthalmology Database study of cataract surgery: Report 1, visual outcomes and complications","volume":"29","author":"Day","year":"2015","journal-title":"Eye"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Therneau, T.M., and Grambsch, P.M. (2000). Modeling Survival Data: Extending the Cox Model, Springer.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Romano, M.R., Catania, F., Confalonieri, F., Zollet, P., Allegrini, D., Sergenti, J., Lanza, F.B., Ferrara, M., and Angi, M. (2021). Vitreoretinal Surgery in the Prevention and Treatment of Toxic Tumour Syndrome in Uveal Melanoma: A Systematic Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810066"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00231356","article-title":"Pars plana vitrectomy in eyes with malignant melanoma","volume":"220","author":"Laqua","year":"1983","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ophtha.2014.06.029","article-title":"Vitreoretinal surgery for complications of choroidal tumor biopsy","volume":"121","author":"Grixti","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/bjophthalmol-2013-303331","article-title":"Pars plana vitrectomy to repair retinal detachment following brachytherapy for uveal melanoma","volume":"97","author":"Beykin","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_32","first-page":"427","article-title":"Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma","volume":"7","author":"Lonngi","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00417-016-3485-9","article-title":"23-mm iodine-125 plaque for uveal melanoma: Benefit of vitrectomy and silicone oil on visual acuity","volume":"254","author":"McCannel","year":"2016","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","article-title":"Plaque radiotherapy for uveal melanomalong-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_35","first-page":"100939","article-title":"Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma","volume":"52","author":"Pors","year":"2025","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tout\u00e9e, A., Angi, M., Dureau, S., L\u00e9vy-Gabriel, C., Rouic, L.L.-L., Dendale, R., Desjardins, L., and Cassoux, N. (2019). Long-Term Visual Outcomes for Small Uveal Melanoma Staged T1 Treated by Proton Beam Radiotherapy. Cancers, 11.","DOI":"10.3390\/cancers11081047"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Espensen, C.A., Appelt, A.L., Fog, L.S., Gothelf, A.B., Thariat, J., and Kiilgaard, J.F. (2019). Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas. Cancers, 11.","DOI":"10.3390\/cancers11081124"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ophtha.2020.06.030","article-title":"Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma","volume":"128","author":"Espensen","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/08820538.2024.2381774","article-title":"Managing vitreoretinal complications in uveal melanoma: Surgical treatment and practical considerations","volume":"40","author":"Anguita","year":"2024","journal-title":"Semin. Ophthalmol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/95\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:57:27Z","timestamp":1766998647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010095"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010095","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}